These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33661923)

  • 1. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
    Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
    PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
    Chen X; Rostad CA; Anderson LJ; Sun HY; Lapp SA; Stephens K; Hussaini L; Gibson T; Rouphael N; Anderson EJ
    Virology; 2021 Jul; 559():1-9. PubMed ID: 33774551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
    Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
    Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
    Díez JM; Romero C; Cruz M; Vandeberg P; Merritt WK; Pradenas E; Trinité B; Blanco J; Clotet B; Willis T; Gajardo R
    J Infect Dis; 2022 Mar; 225(6):938-946. PubMed ID: 34693968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
    Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
    Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
    Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V
    Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
    Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
    Front Immunol; 2021; 12():759688. PubMed ID: 34987505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
    Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions.
    Adeniji OS; Giron LB; Purwar M; Zilberstein NF; Kulkarni AJ; Shaikh MW; Balk RA; Moy JN; Forsyth CB; Liu Q; Dweep H; Kossenkov A; Weiner DB; Keshavarzian A; Landay A; Abdel-Mohsen M
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.
    Siracusano G; Brombin C; Pastori C; Cugnata F; Noviello M; Tassi E; Princi D; Cantoni D; Malnati MS; Maugeri N; Bozzi C; Saretto G; Clementi N; Mancini N; Uberti-Foppa C; Temperton N; Bonini C; Di Serio C; Lopalco L
    Front Immunol; 2021; 12():772239. PubMed ID: 34804064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
    Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.